Following the 1 March 2026 Pharmaceutical Benefits System (PBS) updated listings for ipilimumab and nivolumab for the treatment of immunotherapy sensitive, advanced or metastatic cancers, eviQ has published its first broad indication tumour-agnostic immunotherapy protocol.
Recently, CNSA’s Education Manager, Dr Pammie Ellem, travelled to Darwin to represent the Cancer Nurses Society of Australia and support local cancer nurses through targeted professional development.
People with rare and less common cancers have been given new hope today, with the release of a positive recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC) that, if accepted, would make a potentially life-changing immunotherapy more affordable and available to those who need it.
A new targeted oral therapy is changing the landscape for people with hormone receptor positive, HER2 negative metastatic breast cancer, offering another option for those whose disease has progressed on prior treatment. This practical session will step through how the treatment works, when it is used and what makes its side effect profile distinct.
The Australian Government has announced $1 million to fund projects that build stronger networks between cancer services in outer metropolitan, regional, rural, and remote communities, and larger metropolitan centres.
Australia now has clarity it has never had before: 20,950 Australians are living with metastatic breast cancer — more than double what was previously understood. This new national estimate exposes decades of undercounting, underestimated need, and under-resourced care.
